The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
This protein has been shown to stimulate protein synthesis in L6 myoblasts at an ED50 of ≤ 10 ng/ml.
R3 IGFI is a recombinant analog of human IGF-I that has been specifically engineered for the enhancement of cell culture performance. It is more biologically potent in vitro than either insulin or native IGF-I and has been shown to significantly increase recombinant protein production. It is ideal for both research and large-scale culture systems utilizing serum-free or low-level serum applications. All cells that have a growth response to insulin in cell culture have the potential to respond to R3 IGFI. R3 IGFI is effective in commercially relevant cell types including CHO, PER.C6® and HEK 293. Hybridomas and fibroblasts have also been shown to respond to R3 IGFI.
NOTE: This protein is full length, SwissProt ID P05019. The protein undergoes molecular processing and the IGF1 is full length at aa 49-118. The rest of the sequence is signal peptide and propeptide
Concentration information loading...
Shipped at 4°C. Store at 4°C prior to reconstitution. Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle.
Lyophilized from 0.1M acetic acid
This product is an active protein and may elicit a biological response in vivo, handle with caution.
Dissolve in 100 µl of 10 mM HCl to create a 1mg/ml stock. For concentrations of <1 mg/ml in buffer, a carrier protein should be added to minimize adsorption of the peptide to plastic or glass surfaces. BSA between 1–5 mg/ml is recommended in serum-free conditions. A carrier protein not necessary in serum-supplemented media. Up to 400 ml of buffer soln containing BSA or serum-supplemented medium may be added to the stock soln in the vial and mixed. Long-term storage of <1 mg/ml not recommended.
Insulin-like growth factor I
Mechano growth factor
R3 IGF1 is an 83 amino acid analog of IGF1 comprising the complete human IGF1 sequence with the substition of an Arg(R) for the Glu(E) at position three, hence R3, and a 13 amino acid extension peptide at the N terminus. This analog of IGF1 has been produced with the purpose of increasing the biological activity of the IGF peptide.
Insulin-like growth factors (IGFs), comprise a family of peptides that play important roles in mammalian growth and development. IGF1 mediates many of the growth-promoting effects of growth hormone.
R3 IGF1 is significantly more potent than IGF1. The enhanced potency is due to the decreased binding of Long R3 IGF1 to all known IGF binding proteins. These binding proteins normally inhibit the biological actions of IGF’s.
Recombinant human R3 IGF1 protein (ab58750)参考文献
has not yet been referenced specifically in any publications.